Related Experiment Video
Updated: Jun 24, 2026
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
Published on: July 5, 2011
[Treatment of trigeminal neuralgia with microvascular decompression]
M Sindou1, J M Leston, C Le Guerinel
1Service de neurochirurgie A, département de neurochirurgie, hôpital neurologique Pierre-Wertheimer, 69003 Lyon, France. marc.sindou@chu-lyon.fr
Abstract:
Pure microvascular decompression (MVD) can cure (that is, no pain, no medication) primary trigeminal neuralgia (TN) caused by vascular compression in 75% of patients (90% when compression is pronounced), according to a Kaplan-Meier survival study at 15 years. MRI with high resolution evidences neurovascular conflicts with good reliability. The results were found to be significantly better when the prosthesis implanted to maintain the compressive vessel away was not touching the nerve. This argues in favor of a real decompressive mechanism of the MVD procedure, rather than a conduction block. Because pure MVD generally does not produce hypoesthesia in the painful territory, MVD is the first surgical therapeutic option for patients with neuralgia resistant to anticonvulsive medications.
Insights
Microvascular decompression (MVD) offers a cure for primary trigeminal neuralgia (TN) in many patients. This surgical option is effective, especially when the implant does not touch the nerve, supporting a true decompression mechanism.
Area of Science:
- Neurosurgery
- Neurology
- Medical Imaging
Context:
- Primary trigeminal neuralgia (TN) is a debilitating condition characterized by severe facial pain.
- Vascular compression of the trigeminal nerve is a common cause of primary TN.
- High-resolution MRI reliably identifies neurovascular conflicts.
Purpose:
- To evaluate the long-term efficacy of pure microvascular decompression (MVD) for primary trigeminal neuralgia (TN).
- To investigate the mechanism of action for MVD in treating TN.
- To determine the optimal surgical technique for MVD to maximize patient outcomes.
Summary:
- A 15-year Kaplan-Meier survival study demonstrated that pure MVD can cure primary TN in 75% of patients, with success rates reaching 90% in cases of pronounced vascular compression.
- Outcomes were significantly better when the implanted prosthesis did not contact the nerve, suggesting a true decompressive effect rather than a conduction block.
- Pure MVD is recommended as a primary surgical option for TN patients refractory to anticonvulsant medications, as it typically avoids causing hypoesthesia in the affected area.
Impact:
- Microvascular decompression (MVD) provides a durable, curative treatment for primary trigeminal neuralgia (TN) in a significant majority of patients.
- The findings support MVD as a first-line surgical intervention for medication-resistant TN.
- Understanding the decompressive mechanism of MVD can refine surgical techniques and improve patient selection for optimal results.
